Literature DB >> 14695852

Bortezomib therapy for myeloma.

Kenneth C Anderson.   

Abstract

Entities:  

Year:  2004        PMID： 14695852

Source DB:  PubMed          Journal:  Curr Hematol Rep        ISSN： 1540-3408


× No keyword cloud information.
  10 in total

1.  KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.

Authors:  Sudha Mannava; DaZhong Zhuang; Jayakumar R Nair; Rajat Bansal; Joseph A Wawrzyniak; Shoshanna N Zucker; Emily E Fink; Kalyana C Moparthy; Qiang Hu; Song Liu; Lawrence H Boise; Kelvin P Lee; Mikhail A Nikiforov
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

Authors:  Esther A Obeng; Louise M Carlson; Delia M Gutman; William J Harrington; Kelvin P Lee; Lawrence H Boise
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

3.  Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells.

Authors:  E E Fink; S Mannava; A Bagati; A Bianchi-Smiraglia; J R Nair; K Moparthy; B C Lipchick; M Drokov; A Utley; J Ross; L P Mendeleeva; V G Savchenko; K P Lee; M A Nikiforov
Journal:  Leukemia       Date:  2015-07-24       Impact factor: 11.528

4.  Isoginkgetin, a Natural Biflavonoid Proteasome Inhibitor, Sensitizes Cancer Cells to Apoptosis via Disruption of Lysosomal Homeostasis and Impaired Protein Clearance.

Authors:  Jessica Tsalikis; Mena Abdel-Nour; Armin Farahvash; Matthew T Sorbara; Stephanie Poon; Dana J Philpott; Stephen E Girardin
Journal:  Mol Cell Biol       Date:  2019-04-30       Impact factor: 4.272

5.  The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.

Authors:  Brittany C Lipchick; Adam Utley; Zhannan Han; Sudha Moparthy; Dong Hyun Yun; Anna Bianchi-Smiraglia; David W Wolff; Emily Fink; Liang Liu; Cristina M Furdui; Jingyun Lee; Kelvin P Lee; Mikhail A Nikiforov
Journal:  Blood Adv       Date:  2021-04-13

6.  Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.

Authors:  M Amit-Vazina; S Shishodia; D Harris; Q Van; M Wang; D Weber; R Alexanian; M Talpaz; B B Aggarwal; Z Estrov
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

7.  Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma.

Authors:  Xiaotong Hu; Han Xuan; Huaping Du; Hao Jiang; Jinwen Huang
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

8.  Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.

Authors:  Chao Niu; Haofan Jin; Min Li; Shan Zhu; Lei Zhou; Feng Jin; Yulai Zhou; Dongsheng Xu; Jianting Xu; Lianjing Zhao; Shanshan Hao; Wei Li; Jiuwei Cui
Journal:  Oncotarget       Date:  2017-01-24

9.  A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.

Authors:  Katarina Chroma; Zdenek Skrott; Jan Gursky; Jaroslav Bacovsky; Pavel Moudry; Tereza Buchtova; Martin Mistrik; Jiri Bartek
Journal:  Cell Death Dis       Date:  2022-03-04       Impact factor: 8.469

10.  Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells.

Authors:  K Zhu; K Dunner; D J McConkey
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.